CN104039148A - 组合als疗法 - Google Patents

组合als疗法 Download PDF

Info

Publication number
CN104039148A
CN104039148A CN201280034661.5A CN201280034661A CN104039148A CN 104039148 A CN104039148 A CN 104039148A CN 201280034661 A CN201280034661 A CN 201280034661A CN 104039148 A CN104039148 A CN 104039148A
Authority
CN
China
Prior art keywords
riluzole
dose
administration
experimenter
effective dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280034661.5A
Other languages
English (en)
Chinese (zh)
Inventor
杰西.锡达鲍姆
约翰.毛
法迪.马利克
安德鲁.A.沃尔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Priority to CN201811116043.0A priority Critical patent/CN109316480A/zh
Publication of CN104039148A publication Critical patent/CN104039148A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280034661.5A 2011-07-13 2012-07-12 组合als疗法 Pending CN104039148A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811116043.0A CN109316480A (zh) 2011-07-13 2012-07-12 组合als疗法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201161507381P 2011-07-13 2011-07-13
US61/507,381 2011-07-13
US201161544533P 2011-10-07 2011-10-07
US61/544,533 2011-10-07
US201261637759P 2012-04-24 2012-04-24
US201261637770P 2012-04-24 2012-04-24
US61/637,770 2012-04-24
US61/637,759 2012-04-24
US201261646699P 2012-05-14 2012-05-14
US61/646,699 2012-05-14
PCT/US2012/046523 WO2013010015A2 (en) 2011-07-13 2012-07-12 Combination als therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811116043.0A Division CN109316480A (zh) 2011-07-13 2012-07-12 组合als疗法

Publications (1)

Publication Number Publication Date
CN104039148A true CN104039148A (zh) 2014-09-10

Family

ID=47506929

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280034661.5A Pending CN104039148A (zh) 2011-07-13 2012-07-12 组合als疗法
CN201811116043.0A Pending CN109316480A (zh) 2011-07-13 2012-07-12 组合als疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811116043.0A Pending CN109316480A (zh) 2011-07-13 2012-07-12 组合als疗法

Country Status (16)

Country Link
US (1) US10272082B2 (https=)
EP (1) EP2731611B1 (https=)
JP (2) JP6145946B2 (https=)
KR (1) KR101951220B1 (https=)
CN (2) CN104039148A (https=)
AU (2) AU2012281042B2 (https=)
BR (1) BR112014000742A2 (https=)
CA (1) CA2849213A1 (https=)
EA (2) EA028060B1 (https=)
HK (1) HK1197178A1 (https=)
IL (1) IL230391B (https=)
IN (1) IN2014DN00200A (https=)
PH (1) PH12014500094A1 (https=)
SG (1) SG10201605707UA (https=)
WO (1) WO2013010015A2 (https=)
ZA (1) ZA201400236B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US20160263110A1 (en) * 2013-11-04 2016-09-15 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis
HUE057533T2 (hu) 2014-04-29 2022-05-28 Cytokinetics Inc Eljárások vitálkapacitás csökkenésének gátlására
EA038518B1 (ru) * 2014-11-21 2021-09-09 Биохэйвен Фармасьютикал Холдинг Компани Лтд. Сублингвальный препарат рилузола
MX2017006454A (es) * 2014-11-21 2018-03-23 Biohaven Pharm Holding Co Ltd Administracion sublingual de riluzol.
EP3072513A1 (en) * 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
MX390495B (es) 2016-03-25 2025-03-20 Ab Science Uso de masitinib para el tratamiento de una subpoblación de pacientes con esclerosis lateral amiotrófica.
WO2021055890A1 (en) * 2019-09-20 2021-03-25 Icahn School Of Medicine At Mount Sinai Controlled release formulations of riluzole and their uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030083318A1 (en) * 2001-10-25 2003-05-01 Jean-Pierre Julien Therapy for neurodegenerative diseases
CN101522681A (zh) * 2006-08-02 2009-09-02 赛特凯恩蒂克公司 特定的化学个体、组合物和方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507866A (en) 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
BE788065A (fr) 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation
IT1156732B (it) 1978-05-10 1987-02-04 Roussel Maestretti Spa Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione
US4668686A (en) 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4775674A (en) 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4943573A (en) 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
JPH0641135A (ja) 1992-07-21 1994-02-15 Nippon Soda Co Ltd イミダゾプテリジン誘導体及びその製造方法
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CA2333770A1 (en) 1998-06-04 1999-12-09 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
DE50015443D1 (de) 1999-10-08 2008-12-18 Gruenenthal Gmbh Bicyclische imidazo-5-yl-aminderivate
HUP0203052A3 (en) 1999-10-08 2004-06-28 Gruenenthal Gmbh Bicyclic imidazo-3-yl-amine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
US20040235801A1 (en) * 2001-10-25 2004-11-25 Jean-Pierre Julien Therapy for stroke
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
US20040166137A1 (en) 2002-11-08 2004-08-26 Lackey John William Hetero-substituted benzimidazole compounds and antiviral uses thereof
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
CA2529196A1 (en) 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
EP1646614A4 (en) 2003-07-01 2008-09-10 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
US20050250794A1 (en) 2003-12-19 2005-11-10 Andrew Napper Methods of treating a disorder
JP2007529422A (ja) 2004-01-29 2007-10-25 エリクシアー ファーマシューティカルズ， インコーポレイテッド 抗ウイルス治療
WO2005108374A1 (en) 2004-04-29 2005-11-17 Fmc Corporation Insecticidal diazole and triazole derivatives
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006036883A2 (en) 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
CA2598489A1 (en) 2005-02-16 2006-08-24 Schering Corporation Piperazine-piperidines with cxcr3 antagonist activity
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008016648A2 (en) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
ES2558517T3 (es) 2006-08-02 2016-02-04 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
ATE543819T1 (de) 2006-10-19 2012-02-15 Signal Pharm Llc Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
MX2009007661A (es) 2007-01-19 2009-12-14 Ardea Biosciences Inc Inhibidores de mek.
WO2008121333A1 (en) 2007-03-30 2008-10-09 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
EP2018854A1 (en) * 2007-07-27 2009-01-28 Merz Pharma GmbH & Co. KGaA Novel combinations of neramexane for the treatment of neurodegenerative disorders
EP2244711A4 (en) 2008-02-04 2011-08-24 Cytokinetics Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
US7998976B2 (en) 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
JP2011527317A (ja) * 2008-07-11 2011-10-27 グラクソ グループ リミテッド Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療
CA2744498C (en) 2008-11-25 2017-10-24 University Of Rochester Mlk inhibitors and methods of use
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
RU2012101792A (ru) 2009-06-19 2013-07-27 Нопп Ньюросайенсиз, Инк. Композиции и способы для лечения бокового амиотрофического склероза
SG10201701101YA (en) 2012-04-02 2017-04-27 Cytokinetics Inc Methods for improving diaphragm function
CN111840294A (zh) 2012-04-11 2020-10-30 赛特凯恩蒂克公司 改善对骨骼肌疲劳的抵抗力的方法
HUE057533T2 (hu) 2014-04-29 2022-05-28 Cytokinetics Inc Eljárások vitálkapacitás csökkenésének gátlására

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030083318A1 (en) * 2001-10-25 2003-05-01 Jean-Pierre Julien Therapy for neurodegenerative diseases
CN101522681A (zh) * 2006-08-02 2009-09-02 赛特凯恩蒂克公司 特定的化学个体、组合物和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LORNE ZINMAN ET AL.: "Emerging targets and treatments in amyotrophic lateral sclerosis", 《LANCET NEUROLOGY》, vol. 10, 31 May 2011 (2011-05-31), pages 481 - 490, XP002733876, DOI: 10.1016/S1474-4422(11)70024-2 *

Also Published As

Publication number Publication date
US20140243344A1 (en) 2014-08-28
IN2014DN00200A (https=) 2015-06-05
EP2731611A4 (en) 2015-02-18
AU2012281042B2 (en) 2016-07-14
NZ619924A (en) 2016-02-26
JP2017128610A (ja) 2017-07-27
EP2731611A2 (en) 2014-05-21
WO2013010015A3 (en) 2014-05-15
EA201791043A1 (ru) 2017-09-29
WO2013010015A2 (en) 2013-01-17
IL230391B (en) 2019-03-31
BR112014000742A2 (pt) 2016-08-23
SG10201605707UA (en) 2016-09-29
CA2849213A1 (en) 2013-01-17
AU2012281042A1 (en) 2014-01-30
JP2014520856A (ja) 2014-08-25
KR101951220B1 (ko) 2019-02-22
JP6145946B2 (ja) 2017-06-14
KR20140074270A (ko) 2014-06-17
EA028060B1 (ru) 2017-10-31
AU2016244263A1 (en) 2016-11-03
EA201490011A1 (ru) 2014-08-29
ZA201400236B (en) 2014-10-29
PH12014500094A1 (en) 2014-03-17
HK1197178A1 (en) 2015-01-09
EP2731611B1 (en) 2019-09-18
US10272082B2 (en) 2019-04-30
CN109316480A (zh) 2019-02-12

Similar Documents

Publication Publication Date Title
CN104039148A (zh) 组合als疗法
JP4938905B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
EP3265087B1 (en) Method of treatment with tradipitant
EA020193B1 (ru) Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh)
KR20170092543A (ko) 슈퍼-인핸서 부위에서 전사 조절을 표적화하는 방법
JP2024019691A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
JP2022518944A (ja) 肺動脈性肺高血圧症を治療するための投与レジメンおよび方法
US11571411B2 (en) Use of a bisamide derivative of malonic acid for treating allergic and other diseases in humans and animals
Belavic Drug updates and approvals: 2012 in review
TW201806599A (zh) 用於快速開始抗抑鬱作用之給藥方案
JP6420923B1 (ja) 医薬
MX2014000455A (es) Terapia de combinacion para esclerosis lateral amiotrofica.
US11648252B2 (en) Methotrexate for use as a medicament
NZ619924B2 (en) Combination als therapy
HK40062167A (en) A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl
TW201919704A (zh) 利用吡啶斯的明（pyridostigmine）及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法
Menezes et al. Experimental pharmacological agents in the management of Parkinson’s disease
US20110076334A1 (en) Methods and compositions for treatment of raynaud's phenomenon
TW201919597A (zh) 利用新斯的明（neostigmine）及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法
HK1248552B (en) Method of treatment with tradipitant

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Free format text: FORMER OWNER: CEDARBAUM JESSE MAO JOHN MALIK FADY WOLFF ANDREW A.

Effective date: 20141015

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20141015

Address after: American California

Applicant after: Cytokinetics Inc.

Address before: American California

Applicant before: Cytokinetics Inc.

Applicant before: Jesse Sidabaum

Applicant before: John Mao

Applicant before: Malik Fady

Applicant before: Andrew A. Wolff

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140910